Fig. 3.
Fig. 3. Proportion of patients remaining transfusion free over time is related to platelet transfusion dose. / (A) By treatment cohort. ▴, placebo; ●, PEG-rHuMGDF, 1 μg/kg; ▪, PEG-rHuMGDF, 3 μg/kg. P < .001. (B) By posttransfusion platelet count—3 patient cohorts with highest (●), middle (▴), and lowest (▪) tertile posttransfusion platelet counts.P < .001.

Proportion of patients remaining transfusion free over time is related to platelet transfusion dose.

(A) By treatment cohort. ▴, placebo; ●, PEG-rHuMGDF, 1 μg/kg; ▪, PEG-rHuMGDF, 3 μg/kg. P < .001. (B) By posttransfusion platelet count—3 patient cohorts with highest (●), middle (▴), and lowest (▪) tertile posttransfusion platelet counts.P < .001.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal